You are viewing the site in preview mode
Skip to main content
|
Parameters
|
Total patients (n = 52)
|
Anti-RR-positive patients (n = 10)
|
Anti-RR-negative patients (n = 42)
|
p value
|
|---|
|
Male
|
36 (69%)
|
7 (70%)
|
29 (69%)
|
NS
|
|
Female
|
16 (31%)
|
3 (30%)
|
13 (31%)
|
NS
|
|
Age (years) ± SD
|
54 ± 9
|
53 ± 14
|
54 ± 8
|
NS
|
|
Genotype 1a#
|
12 (23%)
|
3 (30%)
|
9 (21%)
|
NS
|
|
Genotype 1b#
|
39 (75%)
|
7 (70%)
|
32 (76%)
|
NS
|
|
Previous IFN/RBV
|
32 (62%)
|
10 (100%)
|
22 (52%)
|
<0.01
|
|
Treatment outcome
|
|
SVR, no side effects
|
35 (67%)
|
6 (60%)
|
29 (69%)
|
NS
|
|
SVR, but side effects
|
5 (10%)
|
1 (10%)
|
4 (10%)
|
NS
|
|
SVR, combined
|
40 (77%)
|
7 (70%)
|
33 (79%)
|
NS
|
|
Relapse
|
5 (10%)
|
3 (30%)
|
2 (5%)
|
<0.05
|
|
No response
|
7 (13%)
|
0 (0%)
|
7 (17%)
|
NS
|
|
Fisher–Freeman–Halton exact test
| | |
|
Anti-RR positive vs. anti-RR negative, with SVR separated
| |
NS
|
|
Anti-RR positive vs. anti-RR negative, with SVR combined
| |
<0.05
|
- Values presented as n (%) unless otherwise indicated
-
Anti-RR anti-rods/rings autoantibody, IFN/RBV interferon-α/ribavirin therapy, NS not statistically significant (p > 0.05), SD standard deviation, SVR sustained virological response
-
#One patient without anti-RR was genotype 3b
